Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bayer
Femme Max 99 ans
Bayer AG
MAJ Il y a 4 ans
Multicenter, randomized and single-blind (group assigned by chance and unknown to study subjects), comparator-controlled study with all groups running in parallel to investigate the pharmacological effects, drug blood levels and safety of an intrauterine system releasing the study drug BAY 1007626 as compared to Mirena and Jaydess in healthy pre-menopausal women treated for 90 days to determine the study drug dose for further development Klinische Prüfung zur Bestimmung pharmakologischer Eigenschaften, der Wirkstoffkonzentration im Blut und der Sicherheit einer BAY1007626 freisetzenden Gebärmutterspirale im Vergleich mit Mirena und Jaydess bei gesunden, jungen Frauen über 90 Tage zur Bestimmung der Dosis für die weitere Arzneimittelentwicklung
The primary objective of this study is to investigate local and systemic effects of BAY 1007626 on: – Number of bleeding and spotting days, – Endometrial histology, – Ovulation (as surrogate for sy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A multi-center, randomized, double blind, placebo controlled study to investigate the efficacy and safety of Aprotinin on transfusion requirements in patients with bladder cancer undergoing radical or total cystectomy
Main objective: The objective of this study is to evaluate the safety and efficacy of aprotinin as compared to placebo, in reducing the need for subsequent blood transfusion in subjects with bladder c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Medical Institutions of the District Oberpfalz/Bayern (MedBO GmbH)
MAJ Il y a 4 ans
Quetiapine induced neuroplasticity in schizophrenic patients: A combined TMS and VBM study
To evaluate the effect of treatment with quetiapine on aspects of structural neuroplasticity assessed by means of Voxel-based morphometry (changes in gray matter density baseline versus steady-state t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer AG
MAJ Il y a 4 ans
Single-dose study testing rivaroxaban granules to be diluted into an oral suspension in children from 2 months to 12 years with previous blood clot
To characterize the pharmacokinetic profile of rivaroxaban administered as granules for oral suspension
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Study to research BAY 1021189 in patients with worsening heart failure with preserved ejection fraction
To find the optimal dose of BAY 1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment by characterizing the safety, tolerability, pharmacodynamic effects, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer PLC (UK)
MAJ Il y a 4 ans
Lipids in Diabetes Study
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis
The primary objective is to compare the change in FEV1 from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG, D-51368 Leverkusen
MAJ Il y a 4 ans
Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)
To assess the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in treatment naive patients and patients pretreated with an Endothelin Receptor Antagonist or a Prostacyclin a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer AG
MAJ Il y a 4 ans
A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarction. Studie hodnotící bezpečnost a účinnost 6měsíční léčby přípravkem BAY 1142524 podávaného perorálně dvakrát denně, v porovnání s placebem, u pacientů se sníženou ejekční frakcí levé komory po akutním infarktu myokardu
The primary objective of this study is to determine efficacy of BAY 1142524 by investigating the changes in LVEF, EDVI, and ESVI from baseline to 6 months after treatment with 25 mg of BAY 1142524 BID...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bayer Schering Pharma AG
MAJ Il y a 4 ans
A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinylestradiol as beta-cyclodextrin clathrate and 3 mg drospirenone) compared to the conventional regimen of SH T00186D in the treatment of primary dysmenorrhea
To evaluate efficacy and safety of the combined oral contraceptive [COC] SH T00186D (0.02 mg ethinylestradiol [EE]; 3 mg drospirenone [DRSP]) applied in a conventional and an extended flexible regimen...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant